CREATING TRANSFORMATIVE GENE-BASED MEDICINES FOR SERIOUS DISEASES
ABOUT US
At CG Bioengineering, we are employing a novel, non-viral gene delivery and expression platform, the hSynC, to create diverse in vivo and ex vivo therapeutics, spanning a range of disease indications. Guided by this full-spectrum approach, we are committed to making hSynC based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers, genetic and autoimmune diseases.
OUR SCIENCE
Currently developing hSynC – a revolutionary gene delivery/expression platform that can be used to express transformative medicines to treat genetic disease and cell line protein production of relevant targets including antibodies and cytokines. As a gene delivery/expression platform, hSynC as the potential to revolutionize biomedical research and enable medical breakthroughs.
MANAGEMENT
-
CHIEF EXECUTIVE OFFICER
Co-founder and Managing Partner of SynPloid Biotek, LLC, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA) and currently known as CG Bioengineering. Dr. Greene has a scientific background in synthetic chromosome biology. She served as Manager Intellectual Property and Business Development, Chromos Molecular Systems, Inc. (Vancouver, BC Canada). She previously held an academic appointment as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine. Dr. Greene earned her PhD at the University of Iowa (USA) and did post-doctoral work at the National Institutes of Health.
-
Chief Scientific Officer
Dr. Perkins was a co-founder of SynPloid Biotek, LLC, a company founded in 2013 with support from Defense Advanced Research Program Agency (DARPA) and currently known as CG Bioengineering where he continues to serve as the Chief Scientific Officer. Previously, Dr. Perkins was a Professor of Biomedical Sciences (Genetics) at the Mercer University School of Medicine and Distinguished Cancer Scholar, Georgia Cancer Coalition (US). Prior to his appointment at Mercer University School of Medicine, Dr. Perkins was an Assistant Professor of Biochemistry and Duluth Clinic Chair in Molecular Medicine at the Univeristy of Minnesota School of Medicine, Duluth Campus. His work on bioengineering of mammalian synthetic chromosomes over his academic career has been funded by the US National Institutes of Health and the US Defense Advance Research Project Agency (DARPA). Previously, he was a Founding Scientist of Iconix Pharmaceuticals (Mountain View, CA USA) and Director of Chromosome Engineering at Chromos Molecular Systems, Inc. (Vancouver, BC, Canada). He earned his Ph.D. in Biochemistry from Wayne State University School of Medicine (USA) and did his postdoctoral work at the US National Institutes of Health.
BOARD OF DIRECTORS
-
Chairman of the Board of Directors
Mr Batcheller has an extensive background as CEO and Chairman of several life science companies such as Xintela AB, Saga Diagnostics AB, ImmuneBiotech AB and Immodulate Pharma AB. He has a strong track record in the life science industry as a serial entrepreneur, executive decision maker, strategic advisor, board member, dealmaker, and commercial lawyer. Greg has worked with the Business Research group in Asia and Europe since 2014 as a partner and senior advisor.
-
Lead Director
Experienced biotechnology entrepreneur with more than 25 years of experience as an executive, director, investor and advisor in the biotechnology industry. Alistair also is the Co-founder, President and CEO at viDA Therapeutics Inc.
-
Member of CarryGenes Board of Directors since 2020
Mr Dreyer has served as CarryGenes Executive Vice President and Chief Business Officer since 2019. He was the Dean and CEO of the biggest private Business School in Scandinavia and previously a Guest Professor of Tsinghua University Beijing. Mr Dreyer has served as management consultant at Baine, Deloitte and SIAR/Bossard. Later CEO of Business Research Ltd, with consulting operation in Asia and Europe.
Engaging in strategic partnerships.
We look to create value with partners that bring insights into novel biology or technology, creating new opportunities in therapeutic areas of shared interest.
PARTNERS &
RESEARCH SUPPORT
The DMD Project’s mission is to develop a groundbreaking, cell-based therapy program designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Our innovative technology utilizes a non-viral vector system carrying the full dystrophin gene designed to treat DMD. Working in collaboration, our translational approach to product development is based on the strong research foundation provided by our key partnerships.
The Defense Advanced Research Projects Agency (DARPA) is a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military DARPA program encourages research proposals from across academia and industry to develop new platform technologies enabling delivery of therapeutics throughout the body with exceptional efficiency and minimal toxicity.
